Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OTC Sedation Warning Effectiveness To Be Considered By FDA/NTSB

This article was originally published in The Tan Sheet

Executive Summary

The inability of consumers to recognize they have impaired motor skills after taking potentially sedating OTC antihistamines likely will be discussed at a joint FDA/National Transportation Safety Board meeting Nov. 14-15

You may also be interested in...



OTC Sedative Effects Subject Of FDA/NTSB Meeting In November

Data gathered at a November meeting on potential transportation risks associated with the use of sedating medicines by vehicle operators could bolster support for an FDA-mandated OTC switch of second-generation antihistamines.

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Topics

UsernamePublicRestriction

Register

PS093266

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel